Yes Bank announced fairly stable results for Q3FY19 during market hours on Thursday. Bank named Ravneet Gill as the new MD and CEO with effect from March 1. 

Edelweiss Financial Services (EFS) reported a rise of 25 per cent YoY in the total income of Rs. 2,791 crore in Q3FY19 as against Rs. 2,224 core in Q3FY18. However, PAT dropped to Rs. 226 crore in Q3FY19 from Rs. 235 crore in Q3FY18, thereby sinking 4 per cent YoY. 

The company's net profit fell 75 per cent on year-on-year basis, as it had reported a net profit of Rs. 762 crore in the same period last year. The drop in the profit was due to 31 per cent increase in fuel cost and depreciation of the Indian rupee during this quarter when compared to the same period last year.

Leading pharma company Dr. Reddy's Laboratories launches propofol injectable emulsion, USP in the US market. The drug is a therapeutic equivalent and a generic version of anaesthesia drug Diprivan injectable emulsion approved by the US drug regulator.

Following stocks are close to their 52-week low as at 12.45 p.m. on January 24, 2019.

The markets on January 24, 2019 opened gap down. BSE Sensex is trading at 36,097.45, down by 11.02 points and the Nifty is trading at 10,820.75, down by 10.75 points. 

Reclassifying mutual fund categories, SEBI introduced one new category under the broader category of equity schemes, viz. Large & mid-cap category. Let’s find out whether is it worth investing in this new category or you can just ignore it.

Overall volumes in futures & options currently stand at 1.38 crore contracts with a turnover of Rs. 8,22,817.44 crore.

Overall volumes in futures & options currently stand at 1.38 crore contracts with a turnover of Rs. 8,22,817.44 crore.

Going ahead, all eyes would on the key support zone, which is placed around 10,800. As long as the index trades above this level, there would be no structural damage. Stocks in news: MEP Infrastructure Developers, IDBI Bank, Infosys, Bharat Financial Inclusion and Vodafone Idea.